Skip to main content
. 2022 May 3;24(12):2121–2132. doi: 10.1093/neuonc/noac111

Fig. 5.

Fig. 5.

Flowchart for the efficient use of ATRX and HIP1R/VIM for the classification of IDH-mutant gliomas. Tumors with nuclear loss of ATRX can be classified as astrocytoma. Tumors with retained or nondeterminable ATRX status are evaluated with HIP1R/VIM immunohistochemistry. VIM > HIP1R tumors are classified as astrocytomas, VIM < HIP1R are classified as oligodendrogliomas. VIM = HIP1R tumors need molecular 1p/19q testing for classification.